EUVIMEDEUVIMED entdecken
Crossref

Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease

Pei-Jung Lin iD, Adele Levine, Julia Rucker, James D Chambers

Alzheimer's & Dementia · 2023

DOI: 10.1002/alz.12965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Pei-Jung Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massa…. Hauptthemen laut MEDLINE: Medicaid, Alzheimer Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ever since the United States Food and Drug Administration (FDA) approved aducanumab and Centers for Medicare & Medicaid Service (CMS) restricted coverage for the drug, a crucial question has been how other payers will behave. This study examined how Medicaid and commercial plans cover aducanumab.

Methods

We created a database of aducanumab coverage policies issued by Medicaid fee‐for‐service programs (50 states and DC) and 35 of the largest commercial plans (covering ∼ 84% of the commercially insured population).

Results

We found that only 41% of Medicaid fee‐for‐service plans have issued a publicly available coverage policy for aducanumab and that there is wide variation in these coverage criteria. Although the majority of included commercial plans have issued an aducanumab coverage policy, only five plans covered aducanumab for their enrollees. Available coverage polices showed little consistency in how to measure sufficient treatment response.

Discussion

Differences in coverage policies mean that Alzheimer's patients’ access to aducanumab may vary across jurisdictions and across commercial insurers. Highlights Less than half of state Medicaid fee‐for‐service plans issued a publicly available coverage policy for aducanumab. Available Medicaid coverage policies varied substantially in their coverage criteria. The majority of included commercial plans issued an aducanumab coverage policy; only five plans covered aducanumab. Available coverage polices showed little consistency in how to measure sufficient treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidAlzheimer DiseaseHumansAgedUnited StatesMedicareFee-for-Service PlansInsurance CoverageAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Alzheimer's diseaseMedicaidaducanumabdrug coveragehealth insurance

Substanzen

aducanumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.

ORCID-Profile: Pei-Jung Lin

Förderung

  • Alzheimer's Association

Zitieren

APA

Lin, P. J., Levine, A., Rucker, J., & Chambers, J. D. (2023). Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12965

Vancouver

Lin PJ, Levine A, Rucker J, Chambers JD. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease. Alzheimer's & Dementia. 2023. doi:10.1002/alz.12965

BibTeX
@article{Lin2023,
  author = {Lin, Pei-Jung and Levine, Adele and Rucker, Julia and Chambers, James D},
  title = {Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  doi = {10.1002/alz.12965}
}
Kostenlos starten →